Navigation Links
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Date:11/9/2008

l impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.

CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.

In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).

Please see accompanying full Prescribing Information. If you have any questions concerning CRESTOR, please contact AstraZeneca at 1-800-237-8898. CRESTOR is a registered trademark of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... chemo can help avoid treatment toxicity, research shows , ... with immunodeficiencies, researchers may have found a better way ... stem-cell transplants. , A regimen using antibodies instead ... children, according to Dr. Persis J. Amrolia, a doctor ...
... TALLAHASSEE, Fla., Sept. 2 Pharmavite, a global leader in ... to test the impact of shopper education on retail purchasing of ... number of retail stores for a ninety-day trial period, LearnSomething,s ShopperAssist(TM) ... an LCD screen with ten user selectable buttons, shoppers will be ...
... , , THE WOODLANDS, Texas, Sept. 2 ... of America,s fastest-growing private companies - the Inc. 500. Inc. ... the top quarter as #117 with a three-year sales growth of 1,424%. ... are going to change the world, look at the Inc. 500," said ...
... Danaher Corporation (NYSE: DHR ) today announced that ... MDS; NYSE: MDZ ) to acquire the Analytical ... in Applied Biosystems/MDS Sciex joint venture ("AB SCIEX"), a mass ... Molecular Devices Corporation, a bioresearch and analytical instrumentation company. ...
... , , PRINCETON, N.J., ... of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with ... version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral ... oral liquid were $70 million (IMS - MAT: June 2009). ...
... , CINCINNATI, Sept. 2 LCA-Vision Inc. (Nasdaq: ... Lasik Plus ((R)) brand, today announced that members of its executive management ... , FTN Equity Capital Markets Corp. ... 2 at the Grand Hyatt Hotel in New York City; , ...
Cached Medicine News:Health News:New Technique Offers Hope for Kids With Immune Deficiency 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 3Health News:eCardio Included on Inc. Magazine's 28th Annual List of America's Fastest-Growing Private Companies -- the Inc. 500 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 2Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 3Health News:LCA-Vision to Present at September Investment Conferences 2
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... is a compact, stand-alone microprocessor-controlled photometer designed ... 96-well microplates using single- or dual- wavelength ... and a dynamic reading range up to ... any laboratory or assay requirements. Self-diagnostics (up ...
... System is made up of three integral ... and the Merci Balloon Guide Catheter. The ... location of the clot has been identified ... is inserted through a small incision in ...
A 3080/3085 orthopedic extension serves as a mobile, radiolucent orthopedic platform. When not in use, accessories can be removed and stored in cart....
Medicine Products: